Equities

Advanced Medical Solutions Group PLC

Advanced Medical Solutions Group PLC

Actions
Health CareHealth Care Equipment & Services
  • Price (GBX)255.00
  • Today's Change19.00 / 8.05%
  • Shares traded260.85k
  • 1 Year change-24.89%
  • Beta0.4880
Data delayed at least 20 minutes, as of Jun 05 2020 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

Advanced Medical Solutions Group plc is engaged in the design, development, manufacture and distribution of materials for use in advanced woundcare products and surgical dressings, as well as medical adhesives and sutures for closing and sealing tissue. It operates through four segments: Branded Direct, Branded Distributed, OEM (Original Equipment Manufacturer) and Bulk Materials. Its Branded Direct segment is engaged in selling, marketing and innovation of its branded products sold directly by its sales teams. Its Branded Distributed segment is engaged in distribution, marketing and innovation of its brands sold by distributors in markets not serviced by its sales team. Its OEM segment is engaged in selling, marketing and innovation of its products supplied to partners under their brands. Its Bulk Materials segment is engaged in selling, marketing and innovation of bulk materials to medical device partners and convertors. Its products include ActivHeal, LiquiBand and RESORBA.

  • Revenue in GBP (TTM)102.37m
  • Net income in GBP18.92m
  • Incorporated1993
  • Employees747.00
  • Location
    Advanced Medical Solutions Group PLCPremier Park, 33 Road OneWINSFORD CW7 3RTUnited KingdomGBR
  • Phone+44 160 686 3500
  • Fax+44 160 686 3600
  • Websitehttp://www.admedsol.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AMS:LSE since
announced
Transaction
value
Biomatlante SADeal completed02 Dec 201902 Dec 2019Deal completed-2.30%8.81m
Data delayed at least 20 minutes, as of Jun 05 2020 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Creo Medical Group PLC13.47k-15.91m278.02m71.00--3.21--20,640.15-0.1311-0.13110.00010.54970.00020.01660.0101189.72-23.06---24.23--36.75---118,122.90--16.88--0.0086--------------
Avacta Group Plc4.54m-10.42m313.20m119.00--10.23--69.00-0.0822-0.08220.03590.14670.15256.882.7838,142.86-35.00---38.73--75.06---229.48--6.84-253.270.0309--------------
Silence Therapeutics plc244.00k-19.58m379.21m46.00--17.17--1,554.13-0.2592-0.25920.00330.26680.0057--122.005,304.35-46.10-21.95-54.79-23.36-----8,025.41-5,310.29---167.160.0135----74.69-6.36---51.55--
Alliance Pharma plc135.64m25.01m400.90m219.0016.011.4615.022.960.04720.04720.25580.51790.33442.905.30619,347.106.176.427.197.6363.4660.1318.4420.542.058.290.22626.8514.7425.5236.2524.436.84-11.73
Indivior PLC555.82m-75.43m434.31m824.00--14.02--0.7814-0.1095-0.10950.7380.04230.44921.633.49674,540.10-6.1011.73-11.1830.5882.8688.38-13.5714.991.63--0.879612.38-21.89-6.78-50.92-19.77-23.08--
Advanced Medical Solutions Group plc102.37m18.92m507.68m747.0027.052.6520.974.960.08720.08720.47210.88980.47372.583.63137,038.808.7511.409.5712.5059.0859.5618.4820.135.48--0.051413.34-0.224210.19-15.878.0218.8717.23
Vectura Group PLC178.30m-22.10m531.84m480.00--1.2816.622.98-0.0344-0.03440.27350.68590.30953.054.48371,458.30-3.84---4.35--53.45---12.39--1.85--0.0178--11.09--74.94------
Oxford BioMedica plc64.06m-16.07m589.02m500.00--7.77--9.19-0.225-0.2250.8810.9840.544410.462.54128,120.00-13.65-12.93-18.06-17.2844.2455.40-25.08-22.251.88-1.530.0999---4.0736.30-313.05--35.82--
Puretech Health PLC16.01m-5.81m742.36m225.00--2.64--46.38-0.0233-0.02330.05560.98440.0383--4.3271,138.03-13.04-28.57-17.99-45.76-----340.74-865.69----0.2374--718.4619.53-264.91--50.17--
Data as of Jun 05 2020. Currency figures normalised to Advanced Medical Solutions Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

48.76%Per cent of shares held by top holders
HolderShares% Held
Octopus Investments Ltd.as of 08 Apr 202022.74m10.58%
Hargreave Hale Ltd.as of 08 Apr 202015.54m7.23%
AXA Investment Managers UK Ltd.as of 08 Apr 202014.68m6.83%
Investec Wealth & Investment Ltd.as of 08 Apr 20209.98m4.64%
Groupama Asset Management SAas of 08 Apr 20209.79m4.56%
Kames Capital Plcas of 08 Apr 20207.26m3.38%
BlackRock Investment Management (UK) Ltd.as of 08 Apr 20207.24m3.37%
Aviva Investors Global Services Ltd.as of 08 Apr 20206.69m3.11%
CA Indosuez Wealth (Private Banking Europe)as of 02 May 20205.97m2.78%
Rathbone Investment Management Ltd.as of 02 May 20204.90m2.28%
More ▼
Data from 31 Dec 2019 - 30 Apr 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.